PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-4.77
Negative P/E while Biotechnology median is -2.40. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
4.94
P/B exceeding 1.5x Biotechnology median of 1.88. Jim Chanos would check for potential asset write-down risks.
-27.19
Negative FCF while Biotechnology median P/FCF is -9.11. Seth Klarman would investigate cash flow improvement potential.
-27.19
Negative operating cash flow while Biotechnology median P/OCF is -9.08. Seth Klarman would investigate operational improvement potential.
4.94
Fair value ratio exceeding 1.5x Biotechnology median of 1.88. Jim Chanos would check for valuation bubble risks.
-5.24%
Negative earnings while Biotechnology median yield is -6.19%. Seth Klarman would investigate path to profitability.
-3.68%
Negative FCF while Biotechnology median yield is -4.84%. Seth Klarman would investigate cash flow improvement potential.